BetterLife to Present BETR-001 Preclinical Data at 2024 FENS Conference in Vienna

June 26, 2024 -- BetterLife Pharma Inc., a burgeoning biotech firm specializing in the development of innovative treatments for mental health disorders, has announced a significant upcoming presentation by its scientific partners. Drs. Vern Lewis and Argel Aguilar-Valles from Carleton University’s Department of Neuroscience in Ottawa, Canada, will share findings from their study on BETR-001 (2-bromo-LSD) at the FENS conference scheduled for June 25-29 in Vienna, Austria. BETR-001 is a proprietary, non-hallucinogenic LSD derivative patented by BetterLife.

The study, titled “Cortical transcriptomic effects of the non-hallucinogenic 2-Bromo-LSD,” features Dr. Lewis's presentation of preclinical gene sequencing data. This data reveals that BETR-001 activates several crucial signalling pathways associated with neuroplasticity and neurotransmission, which are linked to anxiety and depression. Additionally, the study highlights multiple gene targets involved in axon guidance and addiction.

Dr. Ahmad Doroudian, the CEO of BetterLife, expressed enthusiasm about the preclinical discoveries, noting that they align with previous research on depression and anxiety models. He highlighted that BETR-001 activates key signalling pathways implicated in depressive disorders, suggesting its potential therapeutic benefits may extend beyond mood disorders to include conditions like neurodegeneration and addiction.

BetterLife Pharma Inc. is an emerging player in the biotechnology space with a primary focus on the development and commercialization of two main compounds, BETR-001 and BETR-002, aimed at treating neuro-psychiatric and neurological disorders.

BETR-001, currently in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative. Its uniqueness lies in its unregulated status, which could allow for potential self-administration. BetterLife holds a synthesis patent for BETR-001, which removes regulatory barriers. Additionally, a pending patent covers its composition and method of use for treating major depressive disorder, anxiety disorder, neuropathic pain, and other neuro-psychiatric and neurological conditions.

BETR-002, also in preclinical and IND-enabling studies, is derived from honokiol, an active anxiolytic component of magnolia bark. BetterLife’s pending patent covers formulations and methods of use for treating anxiety-related disorders, including benzodiazepine dependency.

Additionally, BetterLife owns a drug candidate aimed at treating viral infections and is currently exploring strategic options for its further development.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!